Business
New Adagio Medical Publication Highlights Consistent Safety and Effectiveness with Ultralow Temperature Ablation in Broad Range of Patients with Ventricular Tachycardia
LAGUNA HILLS, Calif., February 04, 2026--Adagio Medical Holdings, Inc (Nasdaq: ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced the publication of results from the U.S. Early Feasibility Study ("EFS") evaluating ultralow temperature cardiac ablation ("ULTC") for the treatment of scar-related ventricular tachycardia ("VT"). The study was published in Circulation: Arrythmia and Electrophysiology.
About this update from Adagio Medical Holdings, Inc
[{"type":"text","content":"Early Feasibility Outcomes in a Real-World Patient Cohort of Both Ischemic and Challenging Non-Ischemic Patients Published in Circulation: Arrhythmia and Electrophysiology","length":171,"tagName":"p","attribs":{}},{"type":"text","content":"LAGUNA HILLS, Calif., February 04, 2026--(BUSINESS WIRE)--Adagio Medical Holdings, Inc (Nasdaq: ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced the publication of results from the U.S. Early Feasibility Study ("EFS") evaluating ultralow temperature cardiac ablation ("ULTC") for the treatment of scar-related ventricular tachycardia ("VT"). The study was published in Circulation: Arrythmia and Electrophysiology.","length":562,"tagName":"p"},{"type":"text","content":"The prospective, multi-center study was conducted under the U.S. Food and Drug Administration’s ("FDA’s") EFS program and enrolled 20 patients with both ischemic and non-ischemic cardiomyopathy across four U.S. tertiary referral centers. Investigators evaluated the acute safety and performance of ULTC ablation in patients with drug-refractory scar-related VT.","length":371,"tagName":"p"},{"type":"text","content":"Results demonstrated a favorable safety profile, with no device- or procedure-related major adverse events measured at both seven and 30 days, and strong acute and chronic performance. Among 14 patients with inducible VT tested both before and after ablation, 92.9% achieved non-inducibility of targeted clinical VT. At a mean follow-up of 24 weeks, antiarrhythmic drugs were either completely discontinued or reduced in 72% of the patients, and 83.3% of the patients were free from implantable cardioverter-defibrillator (ICD) shock, with a notable reduction in the overall VT burden.","length":585,"tagName":"p"},{"type":"text","content":""The advantage of Adagio’s ULTC technology in ablation of ventricular tachycardia compared to the conventional technologies is its ability to produce deep, titratable lesions required to treat the significant patient population with deep intramural substrate that cause their VT," said J. Peter Weiss, MD, MSc, Associate Professor of Medicine at the University of Arizona College of Medicine–Phoenix and corresponding author of the st...